di-(tert-butyl) 5-amino-2-pyridinylimidodicarbonate | 509150-44-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: di-(tert-butyl) 5-amino-2-pyridinylimidodicarbonate
• 英文别名: tert-butyl N-(5-aminopyridin-2-yl)-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamate
• CAS: 509150-44-1
• 化学式: C₁₅H₂₃N₃O₄
• 分子量: 309.365
• InChiKey: ZQJPYLCBRQHOKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  94.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  di-(tert-butyl) 5-amino-2-pyridinylimidodicarbonate 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 生成 C₁₉H₁₂ClN₃O₄
  参考文献：
  名称：

  Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core

  摘要：

  This Letter describes the lead optimization of the VU0486321 series of mGlu(1) positive allosteric modulators (PAMs). While first generation PAMs from Roche were reported in the late 1990s, little effort has focused on the development of mGlu(1) PAMs since. New genetic data linking loss-of-function mutant mGlu(1) receptors to schizophrenia, bipolar disorder and other neuropsychiatric disorders has rekindled interest in the target, but the ideal in vivo probe, for example, with good PK, brain penetration and low plasma protein binding, for robust target validation has been lacking. Here we describe the first modifications to the central aryl core of the VU0486321 series, where robust SAR was noted. Moreover, structural variants were identified that imparted selectivity (up to >793-fold) versus mGlu(4). (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.10.013
• 作为产物：
  描述：

  2-氨基-5-硝基吡啶 在 4-二甲氨基吡啶 、 palladium on activated charcoal 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 di-(tert-butyl) 5-amino-2-pyridinylimidodicarbonate
  参考文献：
  名称：

  Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core

  摘要：

  This Letter describes the lead optimization of the VU0486321 series of mGlu(1) positive allosteric modulators (PAMs). While first generation PAMs from Roche were reported in the late 1990s, little effort has focused on the development of mGlu(1) PAMs since. New genetic data linking loss-of-function mutant mGlu(1) receptors to schizophrenia, bipolar disorder and other neuropsychiatric disorders has rekindled interest in the target, but the ideal in vivo probe, for example, with good PK, brain penetration and low plasma protein binding, for robust target validation has been lacking. Here we describe the first modifications to the central aryl core of the VU0486321 series, where robust SAR was noted. Moreover, structural variants were identified that imparted selectivity (up to >793-fold) versus mGlu(4). (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.10.013

文献信息

• [EN] HETEROARYLAMINOISOQUINOLINES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF<br/>[FR] HÉTÉROARYLAMINOISOQUINOLINES, PROCÉDÉS POUR LES PRÉPARER ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：MINORYX THERAPEUTICS S L

  公开号：WO2016120808A1

  公开（公告）日：2016-08-04

  The application is directed to compounds of formula (IA) : and specifically compounds of formula (I) and their salts and solvates, wherein R1, R11, R12, R13, R4, R5, n, A1, A2, and A3 are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.

  该申请涉及式（IA）的化合物，特别涉及式（I）的化合物及其盐和溶剂合物，其中R1、R11、R12、R13、R4、R5、n、A1、A2和A3如规范中所述，以及它们的制备方法，包含它们的药物组合物，以及用于治疗和/或预防与β-半乳糖苷酶活性改变相关的病症的用途，特别是β-半乳糖苷酶1或GLB1，包括GM1神经节苷脂症和莫尔基奥综合征B型。
• Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
  申请人：Erguden Jens

  公开号：US20060183753A1

  公开（公告）日：2006-08-17

  The present invention relates to the use of 2,5-diamidoindole derivatives for the preparation of medicaments for treating urological disorders in humans and/or animals.RCK 41-Foreign Countries

  本发明涉及使用2,5-二氨基吲哚衍生物制备用于治疗人类和/或动物泌尿系统疾病的药物。RCK 41-外国国家。
• Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases
  申请人：Erguden Jens-Kerim

  公开号：US20050038101A1

  公开（公告）日：2005-02-17

  The invention relates to compounds of formula (I), to a method for the production thereof, and to the use of the same as pharmaceuticals for the treatment of diseases in humans and/or animals.

  本发明涉及公式（I）的化合物，其制备方法和将其用作治疗人类和/或动物疾病的药物。
• [EN] USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES<br/>[FR] UTILISATION DE 2,5-DIAMIDOINDOLES SUBSTITUES POUR LE TRAITEMENT DE MALADIES UROLOGIQUES
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004056768A3

  公开（公告）日：2004-08-05
• SUBSTITUIERTE 2,5-DIAMIDOINDOLE ALS ECE-INHIBITOREN ZUR BEHANDLUNG VON KARDIOVASKULÄREN ERKRANKUNGEN
  申请人：Bayer HealthCare AG

  公开号：EP1432415A1

  公开（公告）日：2004-06-30